ArticlePeerJ2025
Gastric intestinal metaplasia subtypes and the effects of c-Myc expression on severity.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential expression of the C-Myc gene in intestinal-type and diffuse-type gastric cancer and its clinical significance.BMC gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: The association between gastric intestinal metaplasia severity grades, histological subtypes, and oncogenic potential remains unclear. This study explored gastric intestinal metaplasia (GIM) subtypes and c-Myc protein expression across mild, moderate, and severe GIM cases. Methods: A total of 180 paraffin-embedded gastroscopy biopsy samples from patients diagnosed with atrophic gastritis were selected, with 60 cases each of mild, moderate, and severe GIM. Alcian blue-Periodic acid-Schiff (AB-PAS) and high iron diamine (HID) staining were used to classify GIM into types I-III. Immunohistochemistry was performed to assess c-Myc expression, with low, moderate, and high expression defined as the percentage of c-Myc-positive cells in the GIM area of <15%, 15-40%, and ≥ 40%, respectively. Spearman and Kruskal-Wallis tests were used to analyze the correlation between GIM severity, GIM subtype, and c-Myc expression. Results: GIM was predominantly diagnosed in middle-aged and elderly individuals. Regarding the subtype, 53.89% were type II, 25.56% were type III, and 20.56% were type I. Low c-Myc expression was present in 47.78% of cases, moderate expression in 36.67%, and high expression in 15.56%. Neither the severity of GIM nor its subtype or c-Myc expression level was correlated with age or sex. Type III GIM accounted for approximately 10% of mild-to-moderate cases, whereas > 50% of severe GIM cases were type III. A positive correlation was found between GIM severity and subtype (r Conclusion: GIM incidence increases with age; however, the histological severity of GIM (as defined by the extent of mucosal gland involvement) within a single biopsy sample does not show a corresponding increase with age. The more severe the GIM is, the greater the proportion of type III GIM cases present. c-Myc expression did not correlate with GIM severity. Conversely, as the GIM subtype becomes more advanced (from type I to type III), c-Myc expression decreases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.